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ABSTRACT  
Objective: To develop a simple, precise, accurate related substance, reverse phase high-performance liquid chomatographic (RP-HPLC) method for 
the quantitative estimation of impurities which are present in dosage form of Tiapride Hydrochloride. 
Methods: The chomatographic separation was achieved with Inertsil C8 (250 × 4.6) mm, 5µ column with mobile phase containing a gradient 
mixture of 0.05 mM aqueous Potassium di hydrogen phosphate (KH2PO4) solution buffer: (with octanesulphonate and final pH of buffer was 
adjusted to 2.7 with Orthophosphoric acid): Acetonitrile: Methanol (800:150:50 v/v), flow rate of 1.5 ml/min and a detection wavelength of 240 nm.  
Results: The method exhibited linearity between range 0.125 to 1200 µg/ml, shows well resolved degradation products from Tiapride 
hydrochloride tablet with 0.063 µg/ml of LOD (limit of detection) and 0.125 µg/ml of LOQ (limit of Quantification). Forced degradation studies 
proved that the method is specific for Tiapride Hydrochloride and N-oxide Tiapride reported in European pharmacopeia and British pharmacopeia 
is one of the degradation impurity confirmed by liquid chromatography mass spectrometry (LC-MS) analysis. 
Conclusion: An accurate, precise, linear, robust and specific related substance RP-HPLC method was developed and validated for the quantitative 
estimation of impurities presented in pharmaceutical dosage form of Tiapride Hydrochloride as per ICH guidelines. The method is stability 
indicating used for separation of degradation products and can be used for the identification of process related impurity. 
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INTRODUCTION  
Tiapride (N-2–Diethylaminoethyl)-2-methoxy-5 methylsulfonyl 
benzamide) hydrochloride is an atypical neuroleptic agent and used 
for the treatment of schizophrenia [1]. It is a selective dopamine D2-
receptor antagonist with little propensity for causing catalepsy and 
sedation. It is likely that the small quantity of these un reacted 
intermediates may left over during the variety of reaction steps and 
finally decrease the yield and quality of the finished products. 
Monitoring of reactions as well as the purity and yield is very 
important to assess the viability of the processes used for the 
commercial production of Tiapride. Thus, there is a great need for 
the development of analytical methods for separation and 
determination of related substances for process development and 
quality control of Tiapride [2-4]. 
 
 
Fig. 1: Structure of tiapride hydrochloride 
 
Literature search revealed that Liquid Chomatography with different 
detection systems such as spectrofluorimetric [5], UV spectrometric 
[6], photodiode array, mass spectrometric was used for quantitative 
determination of Tiapride in biological fluids. Several other 
approaches like cell based assay, immune assay, electrophoretic [7], 
polarimetric and high performance thin layer chomatography 
(HPTLC)[8],gas Chomatography (GC)[9],hydrophilic interaction liquid 
chomatography-tandem mass spectrometry (HILC)[10] have been 
tried to analyse tiapride in various matrices. Japan Pharmacopeia 
(JP)[11] adopted isocratic method for impurity profiling A-E of 
Tiapride API in HPLC, similarly capillary zone electrophoresis (CZE) 
[12] and differential pulse anodic voltametric determination [13] 
method for separation of Tiapride hydrochloride and related 
impurities in pharmaceutical formulations as well as in human urine 
and plasma [14] also reported. European and British pharmacopeia 
has reported related substance reverse phase high performance liquid 
chomatographic method for active pharmaceutical ingredient of 
Tiapride Hydrochloride [15, 16]. But no single method is available for 
formulation and thus it is a challenging task for developing related 
substance method to detect minute amount of impurities in presence 
of pharmaceutical excipients using HPLC. 
Forced degradation studies help to identify reactions that cause 
degradation of pharmaceutical products. They are part of 
development and integral component of validating analytical 
methods that indicate stability and detect impurities, impurities 
formed during manufacturing; storage or use and their properties 
are different from the desired product.  
Any significant degradation product should be evaluated for 
characterization and quantification for its potential hazards [17]. 
The British Pharmacopeia and United State Pharmacopeia have 
also mentioned limits of impurities present in the APIs and 
formulations [18]. The regulatory authorities have also developed 
guidelines regarding stress testing on drug substances and drug 
products to detect the degradation products and degradation 
pathways. It also helps in establishing intrinsic stability of the drug 
substance as well as in developing stability indicating assay 
method [19-22]. 
The present paper describes a reverse phase high-performance 
liquid chomatographic (RP-HPLC) method for separation and 
determination of Tiapride on related impurity by using Inertsil C8 
(250 × 4.6) mm, 5µ column. Mobile phase used in the method was 
the mixture of Buffer: Acetonitrile: Methanol (800:150:50 v/v) 
where the phosphate buffer 0.05 M with pH 2.7 was used. The 
method was validated and found to be suitable for the quality 
assessment of Tiapride in pharmaceutical formulations. 
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MATERIALS AND METHODS 
Chemical and reagents 
All Reagent were of analytical grade acetonitrile (HPLC Grade) was 
purchased from Finar Ltd. Methanol (HPLC Grade), Hydrochloric 
acid were purchased from Merck Specialities Pvt. Ltd., Worli, 
Mumbai. Purified water of Nano pure Diamond water purification 
system. Potssiumdihydrogen, Sodium hydroxide (AR Grade), 
orthophosphate (AR Grade), Hydrogen Peroxide (AR Grade) were 
purchased from Rankem Ltd. Sodium octane sulphonate (AR Grade), 
Orthophosphoric acid (HPLC Grade) were purchased from 
Spectrochem Ltd. Working Standard of Tiapride Hydrochloride was 
purchased from Easybuyer (Hong Kong) Ltd and marketed 
formulation Tiapride hydrochloride Tablet was purchased from 
INTAS Pharmaceutical LTD. Ahmedabad. 
Instrumentation  
Liquid chromatography  
The high performance liquid chromatography (HPLC) System 
consist of Agilent Model of 1100/1200 series with Diode Array 
Detector and quaternary pump with Chomeleon software. pH 
measurement was carried out by PHAN (Lab India LTD) having 
resolution of±0.01 pH and accuracy of±0.01pH was used. pH meter 
was equipped with a combined glass–calomel electrode calibrated 
using standard buffer solutions of pH 4.0, 7.0 and 9.2.  
Computer system was using Chomeleon Software before mobile 
phase delivered in to system. Mobile phase consists of Buffer: 
Acetonitrile: Methanol (800:150:50) where the phosphate buffer 
0.05 M with pH 2.7 was filtered through 0.45 µ nylon filter and 
degassed by sonication for 15 min. HPLC analysis was carried out 
on a Inertsil C8 (250 × 4.6 mm), 5µ manufactured by GL Science at 
40 °C at a flow rate of 1.5 ml/min and the injection volume was 10 
µl. The detection was performed at 240 nm. 
Liquid chomatography mass spectroscopy (LC/MS) 
The liquid chromatography mass spectroscopy (LC/MS) system 
consist of Agilent model of 6400 series of triple quadrupole 
LC/MS with Trap control software. Mobile phase consist of 
gradient programme with mobile phase A (0.1 % Formic Acid) 
and mobile phase B (Acetonitrile HPLC Grade) with pH 2.7 were 
filtered through 0.45 µ nylon filter and degassed by sonication 
for 15 min. LCMS analysis was carried out on Inertsil C8 (250 × 
4.6 mm), 5µ manufactured by GL Science at 40 °C at a flow rate 
of 1.5 ml/min, the injection volume was 10 µl. The detection was 
performed at 240 nm. Mass detection was done by quadrupole 
mass analyser. 
Force degradation studies 
Tiapride Hydrochloride was subjected to different stress 
conditions such as hydrolysis, oxidation, dry heat and photolysis. A 
stock solution of 1000 μg/ml of the drug was prepared in the 
mobile phase. This was used further for all the stress studies. 
Tiapride Hydrochloride was subjected to hydrolytic 
decomposition under acidic condition using 8 ml of 5 M HCl for 24 
hs at 80 °C, under basic condition using 8 ml of 5 M NaOH for 24 
Hs at 80 °C with reflux, and under neutral condition with water at 
80 °C for 24 h. For oxidative stress, the drug was treated with 30% 
H2O2 to reflux at 80 °C for 24 h. For thermal degradation, the solid 
drug and its 1% solution form in water were heated in a stability 
chamber at a temperature of 105 °C/75% relative humidity (RH) 
for 48 h. For photolytic degradation, the solid drug and its 1% 
solution form in water was exposed to the sample to light 
providing an overall illumination of not less than 72 h. 
Sample preparation 
Accurately weighed eight intact tablets (each tablet containing 
Tiapride Hydrochloride API equivalent to 25 mg) containing 200 
mgTiapride Hydrochloride API and transferred into a200 ml 
volumetric flask, then 150 ml of diluent was added and sonicated for 
15 min to disperse the tablets while mixing and resulting solution 
filter though 0.45 µ nylon filter before analysis. 
Validation  
Preparation of solution 
Stock solution of Tiapride hydrochloride was prepared in mobile 
phase as diluent to study accuracy, precision, linearity, limit of 
detection and quantification. The specified concentration of Tiapride 
was taken as 1000 µg/ml. 
Accuracy 
The accuracy of the method was determined by performing the 
recovery studies from previously analysed tablet sample by 
standard addition method at four different levels (LOQ, 50,100,120 
%). Accuracy is performed at range of LOQ Level to 120 % level for 
Tiapride Hydrochloride. 
Precision 
Accurately weighed 8 intact tablets and transferred into 200 ml 
volumetric flask.150 ml of diluent was added and sonicated for 15 
min to disperse the tablets, resulting solution was allowed to cool at 
ambient temperature and volume was made up with diluent, mixed 
well. It was filtered through 0.45 µ nylon filter. 
Robustness 
Robustness was performed by carrying out deliberate changes in 
flow rate (±0.2 ml/min), mobile phase ratio (±5 ml) and pH of the 
mobile phase (±0.2 units), temperature (±0.2 units), variation of 
extraction Time (±5). 
RESULTS AND DISCUSSION  
Stress studies and method development 
Tiapride is a very stable substance, but it can be degraded under 
certain conditions. Several analytical methods were reported for 
determination of Tiapride API including pharmacopeia but no 
method has been reported for the dosage form. Moon Y et al., has 
developed HILIC/MS/MS for determination of Tiapride in human 
plasma. Similarly Metwally et al., described stability indicating 
method for Tiapride in pure form, pharmaceutical preparation and 
in human plasma. In order, to develop an efficient and simple RP-
HPLC method for the analysis of drug in tablet dosage forms, 
preliminary tests were conducted to select optimum and adequate 
chomatographic conditions. Initially Potassium di hydrogen 
phosphate, sodium per chlorate, ammonium acetate was evaluated 
for system suitability parameters and overall chomatographic 
performance. In the sequential trials Potassium di hydrogen 
phosphate was found to be suitable for effective separation of parent 
peak and impurities. 
The pH had an effect on the retention times of the Tiapride and its 
related compounds. Resolutions and peak symmetry are found good 
at pH 2.7. C18, Phenyl and C8 column has been tried but in phenyl 
column impurities were merging with the main peak and in C18 
column good separation was observed but poor peak shape formed. 
 Then again try with Inertsil C8 (250 × 4.6 mm), 5 µm with 
[acetonitrile: methanol: buffer ] 150:52:797 v/v/v and mixture of 
5.44 gm Potassium di hydrogen phosphate (KH2P04) and 0.08 gm of 
sodium octanesulphonate with 1.5 ml/min, column temperature 40 
°C, in order to get good resolution between Tiapride and its 
impurities and get al. l symmetrical peaks. Thus method was finally 
optimised with mixture of 5.44 gm Potassium di hydrogen 
phosphate (KH2P04) and 0.08 gm of sodium octanesulphonate, pH 
adjusted to 2.7 with ortho phosphoric acid and using the ratio of 
buffer: acetonitrile: methanol 800:150:50 v/v/v. 
The force degradation study was carried out in different stress 
conditions. Results obtained concluded that no peaks were detected 
at the retention time of Tiapride peak from the blank and placebo 
preparation. Tiapride Hydrochloride tablet was degraded in 
oxidative, alkali and in acid hydrolytic conditions, all degradation 
products were well separated from Tiapride peak, no degradation 
observed in water stress condition and thermal conditions. Tiapride 
peak was homogenous and spectrally pure in all degradation sample 
preparation of related substance (table 1). 
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Fig. 2: HPLC Chomatogram of test in oxidative condition (30 % H2O2/80 °C, 72 H) 
 
Table 1: Force degradation study of tiapride hydrochloride tablet 
Condition Related substance Peak purity 
Match factor 
% Assay of tiapride % Degradation 
% Single impurity % Total impurity 
Without Degradation 0.046 0.066 997.711 99.9 0 
Hydrolytic Degradation 
(Acid) 5M HCl/80 °C/72 Hs 
4.322 5.379 998.201 94.1  
5.8 
Hydrolytic Degradation 
(Base) 5M NaOH/80 °C/24 Hs 
5.293 6.766 998.334 92.9  
7.00 
Oxidative Degradation 
(80 °C/30 %H2O2/72 Hs) 
6.097 7.323 998.426 91.6 7.00 
Thermal Degradation (105 °C) 0.058 0.148 997.803 99.2 7.7 
Hydrolytic Degradation 
(Water)80 °C/72 Hs 
0.046 0.093 997.864 99.4 ND 
Photo Degradation 
(UV Uncontrolled) 
0.049 0.068 997.938 99.5 ND 
Photo Degradation 
(UV controlled) 
0.045 0.064 997.803 99.6 ND 
 
 




It was observed that deliberate changes made in the method with 
regards to the flow rate, mobile phase composition and the pH of the 
mobile phase did not cause any significant changes in the resolution, 
accuracy and precision indicating that the method is robust. 
Linearity 
The response of the drug was found to be linear over the 
concentration range from 0.125µg/ml to 1200 µg/ml. The 
regression equation was observed to be Y = 16.056x–10.569. 
Specificity 
The method was found to be specific as absence of any interference 
at retention times of peak of interest, and it was evaluated by 
observing the chromatogram of blank samples and samples of 
Tiapride. The elution peak of unknown impurity was separated from 
Tiapride. 
Limits of detection (LOD) and quantification (LOQ) 
Limit of detection, LOD was found to be 0.063µg/ml and the limit of 
quantification, LOQ was found to be 0.125µg/ml using % test 
concentration method. 
Accuracy 
Recovery studies were performed from 0.125 μg/ml to 1200 μg/ml 
for Tiapride.  
The method showed % recovery in the range of 99.3% to 108.0 
% which suggest that the method is accurate. Recovery data is 
given in table 2. 












































































50.0 Smp. Name - Placebo prep._25mg (As such) # 9 Inj. Time 12-12-13 18:26:58  UV_VIS_1mAU
min
WVL:240 nm
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Fig. 4: HPLC chromatogram of standard tiapride HCl (1000 µg/ml) 
 
 
Fig. 5: HPLC chromatogram of tiapride HCl tablet (1000 µg/ml) 
 
Table 2: Results of recovery studies 
Accuracy level Concentration of tiapride (µg/ml) Area Recovered amount of tiapride (µg/ml) %Recovery 
LOQ 0.125 2.17248 0.135 108.0 
2.06807 0.129 103.2 
2.15334 0.134 107.2 
 Mean 106.1 
% RSD 2.42 
50 % 
 
499.99 8038.138 500.611 100.1 
8017.607 499.332 99.9 
8010.751 498.292 99.8 
 Mean 99.9 
% RSD 0.15 
100% 999.991 15953.16 993.555 99.4 
15968.48 994.508 99.5 
15962.62 994.144 99.4 
 Mean 99.4 
% RSD 0.06 
120 % 1199.989 19142.09 1192.159 99.3 
19158.39 1193.175 99.4 
19257.15 1199.325 99.9 
 Mean 99.2 
% RSD 0.32 
 
Precision 
Absolute difference in individual impurity and total impurity of test 
preparation was found to be less than 0.05 and 0.010 respectively. 
Method precision data is represented in table 3. 
Characterization of Impurity by LC/MS study of degraded samples 
10 µg/ml of Tiapride N Oxide impurity solution was injected in liquid 
chromatography system and retention time (RT) was obtained at 
11.884 min (fig. 6). Overlay chromatogram of the reference standard 
of Tiapride N oxide impurity and degradation sample was shown in 
fig. 7. 
Mass spectrum of Tiapride N-Oxide is shown in fig. 8. The molecular 
weight of Tiapride N-oxide is 344 and [M+H]+ion peak obtained at 
m/z 345.08. LC/MS analysis shows peak obtained at RT 9.09 min 
with molecular weight 344 exactly match with Tiapride N-Oxide 
confirmed that this molecular mass was of Tiapride N-Oxide.  
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N-oxide impurity was generated during all degradation conditions. 
Thus, Tiapride N-Oxide is a degradation impurity which is reported 
impurity in European pharmacopeia, Japan pharmacopeia, and 
British pharmacopeia. 
 
Table 3: Results of precision studies 
 %Single Impurity % Total impurities 
No Method precision Intermediate precision Method precision Intermediate precision 
1 0.045 0.048 0.064 0.066 
2 0.045 0.047 0.065 0.065 
3 0.045 0.049 0.064 0.067 
4 0.045 0.049 0.065 0.067 
5 0.046 0.046 0.064 0.064 
6 0.045 0.047 0.065 0.065 
Mean 0.045 0.048 0.065 0.066 
% RSD 1.14 2.54 0.85 1.84 
Absolute difference in mean 0.003 Absolute difference in mean 0.001 
 
 
Fig. 6: Chomatogram of reference standard of n oxide impurity 
 
 
Fig. 7: Overlay HPLC chomatogram of standard impurity N oxide and oxidative degradation sample 
 
 
Fig. 8: Mass spectrum of tiapride n oxide 
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CONCLUSION 
European Pharmacopeia has reported related substance reverse 
phase high performance liquid chomatographic method for the 
active pharmaceutical ingredient of Tiapride Hydrochloride. This 
method is not yet applied for formulations. In current project 
validated method is applied for the formulation and validation was 
carried out as per ICH (Q3) guideline, which confirms that method is 
specific, precise, robust and accurate for the developed formulation 
analysis. This method can also work as stability indicating method as 
it can separate degradation products peak from each other as well as 
from drug peak. The method can also be used as in identification of 
process impurity testing. The impurity Tiapride N-Oxide which is 
reported in European Pharmacopeia, British Pharmacopeia and 
Japan Pharmacopeia is confirmed as a degradation impurity by using 
Liquid chromatography mass spectrometry (LC-MS) analysis. 
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